QIAGEN, Inc., a leading global provider of sample and assay technologies, is headquartered in the United States, with significant operations across Europe and Asia. Founded in 1986, QIAGEN has established itself as a pioneer in the biotechnology industry, focusing on molecular diagnostics, genomics, and bioinformatics. The company offers a diverse range of core products and services, including sample preparation kits, PCR assays, and next-generation sequencing solutions, all designed to enhance the accuracy and efficiency of laboratory workflows. QIAGEN's commitment to innovation has positioned it as a trusted partner in the life sciences sector, with notable achievements such as the development of groundbreaking diagnostic tests. With a strong market presence, QIAGEN continues to lead in providing essential tools for researchers and healthcare professionals, driving advancements in personalised medicine and infectious disease management.
How does QIAGEN, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
QIAGEN, Inc.'s score of 99 is higher than 99% of the industry. This can give you a sense of how well the company is doing compared to its peers.
QIAGEN, Inc., headquartered in the US, currently does not have specific carbon emissions data available for the most recent year. The company is a current subsidiary of Qiagen N.V., which may influence its climate commitments and emissions reporting. As part of its climate strategy, QIAGEN, Inc. inherits various initiatives and targets from its parent company, Qiagen N.V. This includes participation in the Science Based Targets initiative (SBTi) and the Carbon Disclosure Project (CDP), both of which are aimed at reducing greenhouse gas emissions in line with global climate goals. However, specific reduction targets or achievements have not been disclosed for QIAGEN, Inc. at this time. The absence of detailed emissions data and reduction targets suggests that QIAGEN, Inc. is still in the process of establishing its own climate commitments or may rely on the broader corporate strategies set by Qiagen N.V. As the company continues to develop its sustainability initiatives, stakeholders can expect future updates on its carbon emissions and climate action plans.
Access structured emissions data, company-specific emission factors, and source documents
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|
| Scope 1 | 3,661,000 | - | - | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 
| Scope 2 | 8,851,000 | - | - | 00,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 
| Scope 3 | - | - | - | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 
QIAGEN, Inc.'s Scope 3 emissions, which decreased by 4% last year and decreased by approximately 21% since 2020, demonstrating supply chain emissions tracking. Nearly all of their carbon footprint comes from suppliers and value chain emissions, representing nearly all emissions under the GHG Protocol, with "Purchased Goods and Services" being the largest emissions source at 77% of Scope 3 emissions.
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
QIAGEN, Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.